Portola – A High-Risk, High-Return Investment Opportunity
- Portola Pharmaceuticals is looking to launch BevyxXa, the first and only once-daily oral anticoagulant indicated for extended prophylaxis of venous thromboembolism in acutely ill medical patients at high risk.
- The company also awaits CHMP decisions on BevyxXa and AndexXa.
- The company stock is currently down 18% from its 52-week high, offering an attractive entry point.
By S. Mitra, MBA (ISB)
Portola Pharmaceuticals Inc. (NASDAQ:PTLA) received another positive impetus for its stock price when the company reported that its resubmitted Biologics License Application (BLA) for AndexXa® has been found acceptable by the FDA for review. AndexXa is being developed as a universal reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled or life-threatening bleeding event or who require urgent or emergency surgery.
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.